

A Phase II study of Rituxmab for the treatment of Sjogrens Syndrome

ACTRN12605000396628

| | |
|-------------------|---|
| Status | RECRUITING |
| Phase | Phase 2 |
| Sponsor | St Vincent's Hospital / University of New South Wales |
| Enrollment | 10 participants |

Plain Language Summary

This study is testing whether a medication called rituximab (Rituxan) can help treat Sjogren's syndrome. Sjogren's syndrome is an autoimmune condition where the immune system attacks moisture-producing glands, causing severe dry eyes and dry mouth. Rituximab works by reducing a certain type of immune cell. Researchers hope it may reduce symptoms and improve saliva and tear production.

You may be eligible if:

- You are a female
- You have been diagnosed with Sjogren's syndrome according to established European-American criteria
- Your condition has been stable for at least 3 months
- You are not taking aspirin or anti-inflammatory drugs (NSAIDs) within 7 days of biopsies
- You are 18 years of age or older

You may NOT be eligible if:

- Your dry mouth was caused by radiation treatment
- You have had previous salivary gland surgery
- You have a blocked salivary duct
- You are taking certain medications that affect saliva production
- You have previously received rituximab
- You have had a live vaccine within 4 weeks of treatment
- You have a history of cancer, recurring infections, or immune deficiency
- You are pregnant or breastfeeding

Talk to your doctor about whether this trial might be right for you.

Key Eligibility Criteria

Inclusion (1)

- Sjogrens Syndrome according to recently updated European-American criteria, 2. Unchanged Sjogrens Syndrome for at least 3 months 3. no aspirin or NSAID therapy within 7 days of each parotid or labial biopsy.

Exclusion (1)

- radiation-induced xerostomia 2. prior salivary gland surgery 3. known parotid duct obstruction 4. anticholinergic and sympathomimetic therapy 5. prior rituxmab therapy 6. live vaccine within 4 week of therapy 7. history of cancer, recurrent bacterial infections or immunodeficiency 8. pregnancy or breast feeding 9. lab abnormality at screening 7.

Locations (1 total)

Australia

<https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12605000396628>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at anzctr.org.au. Generated by ClinicalTrialsFinder.org.